MicroRNA-155 deficient mice experience heightened kidney toxicity when dosed with cisplatin

Kathryn L Pellegrini1, Tao Han2, Vanesa Bijol3

  • 1Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Insights

MicroRNA 155 (miR-155) deficiency exacerbates cisplatin-induced kidney injury by increasing c-Fos levels. Targeting c-Fos may reduce chemotherapy-related nephrotoxicity.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Genetics

Background:

  • Cisplatin chemotherapy is limited by dose-dependent nephrotoxicity.
  • MicroRNAs (miRNAs) regulate gene expression and cellular processes like apoptosis.
  • miR-155 is upregulated in kidney injury, prompting investigation into its role.

Purpose of the Study:

  • To determine the role of miR-155 in cisplatin-induced nephrotoxicity.
  • To investigate the molecular mechanisms underlying miR-155's effect on kidney injury.

Main Methods:

  • Cisplatin treatment of wild-type and miR-155 knockout mice.
  • Assessment of kidney injury levels.
  • Genome-wide expression profiling and bioinformatic analysis.
  • Validation of c-Fos as a direct miR-155 target.

Main Results:

  • miR-155 deficient mice exhibited significantly higher cisplatin-induced kidney injury.
  • Activation of apoptosis and oxidative stress pathways was observed.
  • c-Fos mRNA and protein levels were significantly elevated in miR-155 deficient mice post-cisplatin exposure.

Conclusions:

  • miR-155 plays a protective role against cisplatin-induced nephrotoxicity.
  • Elevated c-Fos in miR-155 deficient mice contributes to kidney injury.
  • Targeting c-Fos presents a potential strategy to mitigate cisplatin nephrotoxicity.

Related Concept Videos